GC Biopharma Corp

GC Biopharma Corp has a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing, and a current ratio of 1.55, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's operating cash flow is negative at -95.2 billion KRW, and its free cash flow is also negative at -2.03 billion KRW, signaling potential liquidity constraints. The company's capital expenditures amounted to -25.9 billion KRW, indicating significant investment in long-term assets.

The company's profitability metrics are weak, with a return on equity of -0.55% and a return on assets of -0.25%, both significantly below the industry median for pharmaceutical companies. These figures suggest that the company is not generating sufficient returns to cover its cost of capital, which could impact its long-term sustainability and ability to fund future growth initiatives.

GC Biopharma Corp's revenue is concentrated in a few key segments, with the majority of its revenue derived from oncology and autoimmune disease treatments. The company's geographic exposure is primarily within South Korea, with limited international operations, which may limit its growth potential in more mature markets. This concentration could expose the company to regulatory and market-specific risks, particularly in its domestic market.

The company's revenue for the latest period was 417.4 billion KRW, and while the outlook for the current fiscal year is uncertain, the company is expected to face challenges in maintaining or growing its revenue in the near term. The negative net income of -6.94 billion KRW and the negative operating income of 17.34 billion KRW indicate that the company is currently not profitable and may need to implement cost-cutting measures or increase revenue to improve its financial position.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to secure additional financing to meet its obligations. The company's capital structure, with a high proportion of long-term debt, may also increase its financial risk, particularly if interest rates rise or if the company's credit rating is downgraded.

Recent events, including analyst estimates and price targets, suggest that the market has a cautiously optimistic view of the company's future performance. The mean price target of 205,400 KRW and the median price target of 205,000 KRW indicate that analysts expect the stock to perform in line with or slightly above its current price. The mean recommendation of 1.55, with five strong-buy and six buy ratings, further supports this view. However, the absence of hold ratings suggests that there is a consensus among analysts that the company has potential for growth.

GC Biopharma Corp (006280.KS) has been formally classified within the Healthcare economic sector and the Pharmaceuticals activity category, marking a significant structural update to its corporate profile. This taxonomy classification, which carries medium severity, establishes the company’s operational identity within the broader market framework, providing clarity on its primary business focus for investors and analysts. Alongside this sectoral definition, the company’s risk assessment profile has been initialized with specific metrics. Dilution risk is now rated as low, suggesting a stable capital structure with minimal immediate threat of share value erosion from new issuances. This low dilution risk is a positive indicator for existing shareholders, implying that management is likely prioritizing capital efficiency or organic growth over aggressive equity financing. Conversely, liquidity risk has been assessed at a medium level. This rating indicates that while the company is not in immediate distress, there may be moderate constraints on its ability to meet short-term obligations or trade shares with high volume without impacting price. Investors should monitor this metric closely, as medium liquidity risk can affect trading costs and price stability, particularly in volatile market conditions. The company currently operates with a lean executive structure, reporting only one officer, and maintains coverage from five analysts. With no index memberships or disclosed top holders, GC Biopharma appears to be a smaller-cap entity where these newly established risk and taxonomy metrics provide foundational data for valuation and risk management. The combination of low dilution risk and medium liquidity risk suggests a company that is capital-conservative but may face some trading or cash flow constraints typical of smaller pharmaceutical firms.

Analysts project 66.7% upside to a mean price target of 205,400 KRW, signaling strong market confidence.

Revenue grew 18.5% year-over-year to 1.99 trillion KRW in FY2026, demonstrating robust top-line expansion.

Net income improved 82.2% year-over-year in FY2026, indicating a significant reduction in losses.

Cash conversion of 13.73 is best-in-class compared to the pharmaceutical cohort median of 0.95.

Gross profit increased to 554.1 billion KRW in FY2026, supporting potential for future margin recovery.

Long-term debt surged to 982.1 billion KRW in FY2026, creating a high credit risk profile.

Debt-to-equity ratio of 0.71 places the company in the bottom quartile of its peer cohort.

Revenue KRW 435.53B, +13,5% YoY.

• ▍Revenue KRW 435.53B, +13,5% YoY

Revenue KRW 497.75B, +12,9% YoY; Operating income −225,9% YoY.

• ▍Revenue KRW 497.75B, +12,9% YoY
• ▍Operating income −225,9% YoY
• ▍Net income −223,5% YoY
• ▍Free cash flow −335,2% YoY
• ▍Net margin -17.7%

Revenue KRW 609.49B, +31,1% YoY; Operating income −25,9% YoY.

• ▍Revenue KRW 609.49B, +31,1% YoY
• ▍Operating income −25,9% YoY
• ▍Net income −52,1% YoY
• ▍Free cash flow −104,7% YoY
• ▍Net margin 2.6%

Revenue KRW 500.26B, +19,9% YoY; Operating income +293,3% YoY.

• ▍Revenue KRW 500.26B, +19,9% YoY
• ▍Operating income +293,3% YoY
• ▍Net income +647,8% YoY
• ▍Free cash flow +1 897,2% YoY
• ▍Net margin 7.6%

Revenue KRW 383.78B; Operating income KRW 8.76B.

• ▍Revenue KRW 383.78B
• ▍Operating income KRW 8.76B
• ▍Net margin 7.7%

Revenue KRW 440.85B; Operating income -KRW 27.67B.

• ▍Revenue KRW 440.85B
• ▍Operating income -KRW 27.67B
• ▍Net margin -6.2%

Revenue KRW 464.87B; Operating income KRW 39.76B.

• ▍Revenue KRW 464.87B
• ▍Operating income KRW 39.76B
• ▍Net margin 7.2%

Revenue KRW 417.36B; Operating income KRW 17.34B.

• ▍Revenue KRW 417.36B
• ▍Operating income KRW 17.34B
• ▍Net margin -1.7%

Revenue KRW 1.99T, +18,5% YoY; Operating income +11,9% YoY.

• ▍Revenue KRW 1.99T, +18,5% YoY
• ▍Operating income +11,9% YoY
• ▍Net income +82,2% YoY
• ▍Free cash flow −182,1% YoY
• ▍Net margin -0.2%

Revenue KRW 1.68T, +3,3% YoY; Operating income −57,8% YoY.

• ▍Revenue KRW 1.68T, +3,3% YoY
• ▍Operating income −57,8% YoY
• ▍Net income +1,3% YoY
• ▍Free cash flow +75,1% YoY
• ▍Net margin -1.6%

Revenue KRW 1.63T, −5,0% YoY; Operating income −71,7% YoY.

• ▍Revenue KRW 1.63T, −5,0% YoY
• ▍Operating income −71,7% YoY
• ▍Net income −140,7% YoY
• ▍Free cash flow −692,5% YoY
• ▍Net margin -1.6%

Revenue KRW 1.71T, +11,3% YoY; Operating income +48,6% YoY.

• ▍Revenue KRW 1.71T, +11,3% YoY
• ▍Operating income +48,6% YoY
• ▍Net income −46,9% YoY
• ▍Free cash flow −68,3% YoY
• ▍Net margin 3.8%